Chronic Renal Failure in Lung Transplant Recipients is Predicted by Tacrolimus Toxicity Events

AMR in patient 1).During therapy, one patient experienced grade IV thrombocytopenia; otherwise, side effects were mild and transient.Prior to AMR, all patients had normal graft function; however, all 3 patients surviving to hospital discharge developed chronic, severe graft dysfunction.Two of the 5 patients are still alive 132 (2) and 230 (5) days after treatment for AMR.Conclusions: Although these preliminary results do not support a strong clinical or immunological response to bortezomib, we cannot exclude a prescribing bias for use in more severe cases of AMR.Bortezomib treatment for AMR warrants further investigation to fully elucidate its potential benefit.